Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm
06:52pm, Thursday, 23'rd May 2024
LOS ANGELES , May 23, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biogen Inc. ("Biogen" or "the Compa
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
11:11am, Thursday, 23'rd May 2024
Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.
SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements re: Biogen business and prospects, resulting in its stock trading at inflated prices.
Biogen Buys Biotech Firm HI-Bio to Boost Its Immunology Portfolio
08:00pm, Wednesday, 22'nd May 2024
Biogen (BIIB) announced Wednesday it had purchased privately-held Human Immunology Biosciences (HI-Bio) for at least $1.15 billion to expand its reach into immunology medicines.
Pomerantz Law Firm Announces the Filing of a Class Action Against Biogen Inc. and Certain Officers - BIIB
07:30pm, Wednesday, 22'nd May 2024
NEW YORK , May 22, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the"Company") (NASDAQ: BIIB) and certain officers. The class
Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfront and up to $650 million in milestone payments
07:42am, Wednesday, 22'nd May 2024
Biogen Inc. BIIB, -1.68% said Wednesday it's acquiring privately held Human Immunology Biosciences for $1.15 billion upfront and up to $650 million in potential milestone payments in a move aimed at b
Biogen to buy Human Immunology Biosciences in up to $1.8 bln deal
07:38am, Wednesday, 22'nd May 2024
Biogen said on Wednesday it had agreed to buy privately held Human Immunology Biosciences for $1.15 billion in upfront and up to $650 million in potential milestone payments.
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
07:30am, Wednesday, 22'nd May 2024
CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnolog
Why Biogen Inc. (BIIB) is a Top Momentum Stock for the Long-Term
10:51am, Tuesday, 21'st May 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Meridian Wealth Management LLC Cuts Stake in Biogen Inc. (NASDAQ:BIIB)
07:26am, Monday, 20'th May 2024
Meridian Wealth Management LLC decreased its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 79.2% during the fourth quarter, according to its most recent filing with the SEC. T
Biogen and Ionis Pharma shares slide as they end development of ALS treatment
02:07pm, Thursday, 16'th May 2024
The stocks of Biogen Inc. and Ionis Pharmaceuticals Inc. were lower Thursday, after the partners said they were terminating development of a treatment for the fatal disease Amyotrophic Lateral Scleros
Biogen, Ionis to discontinue development of ALS drug
07:41am, Thursday, 16'th May 2024
Biogen and Ionis Pharmaceuticals said on Thursday they will terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after failing to show improvement in patie
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
07:30am, Thursday, 16'th May 2024
CAMBRIDGE, Mass. and CARLSBAD, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced the decision to terminate development of BII
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
07:30am, Thursday, 16'th May 2024
Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis cont
Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
01:15pm, Wednesday, 15'th May 2024
Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's di
